173 related articles for article (PubMed ID: 31640718)
21. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
22. Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology.
Hantson A; Fikkert V; Van Remoortel B; Pannecouque C; Cherepanov P; Matthews B; Holan G; De Clercq E; Vandamme AM; Debyser Z; Witvrouw M
Antivir Chem Chemother; 2005; 16(4):253-66. PubMed ID: 16130523
[TBL] [Abstract][Full Text] [Related]
23. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
24. Designing a soluble near full-length HIV-1 gp41 trimer.
Gao G; Wieczorek L; Peachman KK; Polonis VR; Alving CR; Rao M; Rao VB
J Biol Chem; 2013 Jan; 288(1):234-46. PubMed ID: 23184960
[TBL] [Abstract][Full Text] [Related]
25. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
[TBL] [Abstract][Full Text] [Related]
26. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
27. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.
Eggink D; Bontjer I; Langedijk JP; Berkhout B; Sanders RW
J Virol; 2011 Oct; 85(20):10785-97. PubMed ID: 21835789
[TBL] [Abstract][Full Text] [Related]
28. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
29. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
30. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
Hermann FG; Egerer L; Brauer F; Gerum C; Schwalbe H; Dietrich U; von Laer D
J Virol; 2009 May; 83(10):4844-53. PubMed ID: 19279116
[TBL] [Abstract][Full Text] [Related]
31. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antiviral Res; 2003 Jul; 59(2):137-42. PubMed ID: 12895697
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
34. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
35. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
Jang DH; Yoon CH; Choi BS; Chung YS; Kim HY; Chi SG; Kim SS
J Korean Med Sci; 2014 Mar; 29(3):456-9. PubMed ID: 24616600
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41.
Cole AL; Yang OO; Warren AD; Waring AJ; Lehrer RI; Cole AM
J Immunol; 2006 Jun; 176(11):6900-5. PubMed ID: 16709850
[TBL] [Abstract][Full Text] [Related]
38. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
[TBL] [Abstract][Full Text] [Related]
40. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
